Adagene Inc ADR (ADAG)

$1.92 +0.02 (1.05%)
Market Cap 90.45M
Revenue (ttm) 100,000.00
Net Income (ttm) -33.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -33,420.00%
Debt to Equity Ratio 0.26
Volume 900
Avg Vol 38,728
Day's Range N/A - N/A
Shares Out 47.11M
Stochastic %K 29%
Beta 0.74
Analysts Sell
Price Target $5.75

Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/met...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 512 8777 3632
Address:
Building C14, 4th Floor No. 218, Xinghu Street Suzhou Industrial Park, Suzhou, China
RollingDollars
RollingDollars May. 23 at 4:44 PM
$ADAG
0 · Reply
RollingDollars
RollingDollars May. 12 at 6:40 PM
$ADAG ..
0 · Reply
JarvisFlow
JarvisFlow Apr. 3 at 11:00 AM
HC Wainwright & Co. has updated their rating for Adagene ( $ADAG ) to Buy with a price target of 8.
0 · Reply
Lowlow1
Lowlow1 Apr. 1 at 6:36 PM
$ADAG Agmh very good price to jump in at 0.042 has to get to a dollar soon if I post again mybad we are holding over here.......
0 · Reply
PantySniffer69420
PantySniffer69420 Feb. 21 at 2:56 PM
$ADAG I’m finally green! Let’s go!
0 · Reply
ajmrtxl
ajmrtxl Feb. 19 at 5:04 PM
$ADAG's current squeeze data
0 · Reply
fort_cc
fort_cc Feb. 8 at 1:49 AM
$ADAG another disgusting chinese micro bio-med that almost never seems to have its day
0 · Reply
Wisp_Mason09
Wisp_Mason09 Jan. 30 at 11:10 AM
🔥 That’s it !!! 🥁💥🤫 MYNZ PR is coming tomorrow 🚨 Follow the sign, loading up🚀🔥🔥🔥 Petra recently also hinted on X, all the buzz on Pfizer and Astrazeneca is real? LFG $ACRV $ACTU $ADAG
0 · Reply
RollingDollars
RollingDollars Jan. 27 at 1:57 PM
$ADAG
0 · Reply
RollingDollars
RollingDollars Jan. 24 at 2:31 PM
$ADAG
0 · Reply
Latest News on ADAG
Adagene to Present at Jefferies Global Healthcare Conference 2025

May 27, 2025, 7:30 AM EDT - 4 weeks ago

Adagene to Present at Jefferies Global Healthcare Conference 2025

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:05 PM EDT - 5 weeks ago

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Apr 28, 2025, 8:00 AM EDT - 2 months ago

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 2 months ago

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Mar 13, 2025, 8:00 AM EDT - 3 months ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Adagene to Present at Leerink's Global Healthcare Conference 2025

Mar 6, 2025, 8:00 AM EST - 4 months ago

Adagene to Present at Leerink's Global Healthcare Conference 2025

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Feb 27, 2025, 8:00 AM EST - 4 months ago

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Jan 29, 2025, 6:14 AM EST - 5 months ago

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Jan 21, 2025, 5:00 PM EST - 5 months ago

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Nov 7, 2024, 10:01 AM EST - 8 months ago

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 9 months ago

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Sep 16, 2024, 3:01 AM EDT - 10 months ago

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

Jul 12, 2024, 7:00 AM EDT - 1 year ago

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

Adagene to Present at Investor Conferences in June

May 22, 2024, 4:45 PM EDT - 1 year ago

Adagene to Present at Investor Conferences in June

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 9:00 AM EDT - 1 year ago

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Mar 7, 2024, 4:01 PM EST - 1 year ago

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Feb 9, 2024, 6:00 AM EST - 1 year ago

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jan 16, 2024, 5:01 PM EST - 1 year ago

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Jan 4, 2024, 5:00 AM EST - 1 year ago

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Oct 12, 2023, 8:00 AM EDT - 1 year ago

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Adagene to Present at Investor and Scientific Conferences in September

Sep 7, 2023, 6:00 AM EDT - 1 year ago

Adagene to Present at Investor and Scientific Conferences in September

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

Aug 31, 2023, 7:32 AM EDT - 1 year ago

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

May 4, 2023, 9:00 AM EDT - 2 years ago

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

Adagene Announces Updates to its Board of Directors

Apr 28, 2023, 7:00 AM EDT - 2 years ago

Adagene Announces Updates to its Board of Directors

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Apr 18, 2023, 9:17 AM EDT - 2 years ago

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 28, 2023, 4:30 PM EDT - 2 years ago

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

Mar 14, 2023, 6:00 PM EDT - 2 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

Mar 5, 2023, 7:39 PM EST - 2 years ago

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

Jan 9, 2023, 7:00 AM EST - 2 years ago

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

Jan 5, 2023, 4:01 PM EST - 2 years ago

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Dec 16, 2022, 6:30 AM EST - 2 years ago

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

Nov 21, 2022, 4:05 PM EST - 2 years ago

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Nov 10, 2022, 9:05 AM EST - 2 years ago

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November

Oct 11, 2022, 4:03 PM EDT - 2 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Sep 10, 2022, 4:13 AM EDT - 3 years ago

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

Aug 30, 2022, 5:25 PM EDT - 3 years ago

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

Jun 29, 2022, 4:05 PM EDT - 3 years ago

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

May 26, 2022, 5:00 PM EDT - 3 years ago

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

Adagene to Participate in Investor Conferences in May and June

May 12, 2022, 7:00 AM EDT - 3 years ago

Adagene to Participate in Investor Conferences in May and June

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

Apr 8, 2022, 1:09 PM EDT - 3 years ago

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

Mar 31, 2022, 8:30 AM EDT - 3 years ago

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

Mar 16, 2022, 10:07 AM EDT - 3 years ago

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

Mar 16, 2022, 7:00 AM EDT - 3 years ago

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

Mar 10, 2022, 5:30 PM EST - 3 years ago

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

AMGN LLY

Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

Mar 8, 2022, 5:28 PM EST - 3 years ago

Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

Mar 2, 2022, 9:55 AM EST - 3 years ago

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

SNY

Sanofi to pay up to $2.5 billion in deal with Adagene

Mar 2, 2022, 8:22 AM EST - 3 years ago

Sanofi to pay up to $2.5 billion in deal with Adagene

SNY

RollingDollars
RollingDollars May. 23 at 4:44 PM
$ADAG
0 · Reply
RollingDollars
RollingDollars May. 12 at 6:40 PM
$ADAG ..
0 · Reply
JarvisFlow
JarvisFlow Apr. 3 at 11:00 AM
HC Wainwright & Co. has updated their rating for Adagene ( $ADAG ) to Buy with a price target of 8.
0 · Reply
Lowlow1
Lowlow1 Apr. 1 at 6:36 PM
$ADAG Agmh very good price to jump in at 0.042 has to get to a dollar soon if I post again mybad we are holding over here.......
0 · Reply
PantySniffer69420
PantySniffer69420 Feb. 21 at 2:56 PM
$ADAG I’m finally green! Let’s go!
0 · Reply
ajmrtxl
ajmrtxl Feb. 19 at 5:04 PM
$ADAG's current squeeze data
0 · Reply
fort_cc
fort_cc Feb. 8 at 1:49 AM
$ADAG another disgusting chinese micro bio-med that almost never seems to have its day
0 · Reply
Wisp_Mason09
Wisp_Mason09 Jan. 30 at 11:10 AM
🔥 That’s it !!! 🥁💥🤫 MYNZ PR is coming tomorrow 🚨 Follow the sign, loading up🚀🔥🔥🔥 Petra recently also hinted on X, all the buzz on Pfizer and Astrazeneca is real? LFG $ACRV $ACTU $ADAG
0 · Reply
RollingDollars
RollingDollars Jan. 27 at 1:57 PM
$ADAG
0 · Reply
RollingDollars
RollingDollars Jan. 24 at 2:31 PM
$ADAG
0 · Reply
RollingDollars
RollingDollars Jan. 24 at 11:40 AM
$ADAG
0 · Reply
Stmkr
Stmkr Jan. 22 at 3:42 PM
$ADAG Very unimpressive data.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jan. 22 at 9:06 AM
WATCHLIST JAN 22 2025 $ADAG Adagene To Share Updated Clinical Data From ADG126 In Microsatellite Stable Colorectal Cancer At ASCO Gastrointestinal Cancers Symposium On January 25, 2025. $NBIX Neurocrine Announced Publication Of Supplement On Classic Congenital Adrenal Hyperplasia In The Journal Of Clinical Endocrinology & Metabolism, Covering Clinical, Psychosocial, Treatment Challenge $RCL Royal Caribbean Inks Deal Agreement With Chantiers de l'Atlantique To Order Sixth Edge Series Ship For Delivery To Celebrity Cruises In 2028 $VALN Valneva shares are trading higher after the company announced its vaccine showed a sustained immune response in adolescents a year after a single shot. $SLB Citigroup Maintains Buy on Schlumberger, Raises Price Target to $54
0 · Reply
Scooter0732
Scooter0732 Jan. 22 at 5:22 AM
$ADAG bioturd games here Overall their 20mg dosing strategy failed for lack of safety. They created sub groups then sub groups of the sub groups NLMP to shoe horn more impressive numbers. The study population had less lines of therapy than agenus as well. Promising but botensilimab is still 👑. Now time for the investigators to get easy money Saturday.
0 · Reply
Fingerlickengood
Fingerlickengood Jan. 17 at 5:42 PM
$CHRS I don't know anything about $ADAG, but looking at their monoclonal antibody pipelines and the lead scientists involved in 'both' CHS-388 and ADG-126, I could see these two companies doing some great work together if they so chose.....keeping both on my radar!
0 · Reply
PantySniffer69420
PantySniffer69420 Dec. 31 at 4:41 PM
$ADAG I’m in big today. Let’s see…
0 · Reply
PantySniffer69420
PantySniffer69420 Dec. 30 at 6:53 PM
$ADAG Big bull.
0 · Reply
codequest
codequest Dec. 30 at 12:30 PM
$STEC .92 chinese stock lookimg very good, $HAO currently the cheapest chinese stock with strong weekly. $ADAG also look
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 15 at 9:02 PM
RECAP 11/15 +Pos Comments: $ECG + Stifel $LMB + Stifel $BJ + M Science $DECK + M Science RECAP 11/15 -Neg Comments: $BLUE - BofA $ADAG - Jefferies Live Breaking trading news www.openoutcrier.com
0 · Reply
topstockalerts
topstockalerts Nov. 15 at 4:06 PM
Top Gainers PT2 $BE $ADAG $CYD $LGCY $RCAT Details: https://topstockalerts.com/market-gainers-and-losers/
0 · Reply
Bornjever
Bornjever Nov. 15 at 3:39 PM
$ADAG $INO actually I have to thank u for waking me up on doing more research on MYNZ so I could see potential!!!
0 · Reply